Aetna, An­them ex­pected to con­tinue pos­i­tive earn­ings news

Modern Healthcare - - The Week Ahead - —Matthew We­in­stock

OCT. 30: Aetna’s run of solid earn­ings re­ports is ex­pected to con­tinue with its third-quar­ter re­sults. Zacks In­vest­ment Re­search pre­dicts a 2% rise in rev­enue from the same pe­riod last year, to­tal­ing $15.24 bil­lion. Don’t ex­pect any de­tailed in­sights on Aetna’s pend­ing deal to join CVS Health though; the com­pany is not hold­ing an earn­ings call. That trans­ac­tion, which got con­di­tional clear­ance from the Jus­tice De­part­ment, did hit a speed bump. Maria Vullo, head of New York state’s de­part­ment of fi­nan­cial ser­vices, at a pub­lic hear­ing this month raised sev­eral con­cerns about po­ten­tial cost in­creases on New York­ers.

HCA Health­care is ex­pected to de­liver good news with its third-quar­ter earn­ings. Frank Mor­gan, an an­a­lyst with RBC Cap­i­tal Mar­kets, this month wrote that HCA “con­tin­ues to de­liver, with strong re­sults for the year to date and EBITDA growth ahead of its long-term tar­get.” Bar­clays pro­jected that the Nashville-based for-profit sys­tem will see a 2.5% bump in same-fa­cil­ity acute­care ad­mis­sions.

Other com­pa­nies post­ing earn­ings in­clude drug­mak­ers Am­gen and Pfizer.

OCT. 30-NOV. 2: For a few years now, chief in­for­ma­tion of­fi­cers have been push­ing to have a more strate­gic voice in the C-suite. That’s ev­i­denced by the top­ics on tap at the Col­lege of Health­care In­for­ma­tion Man­age­ment Ex­ec­u­tives’ an­nual meet­ing: how M& A ac­tiv­ity im­pacts health IT strat­egy, im­prov­ing clin­i­cal path­ways, and, of course, the now ubiq­ui­tous topic of see­ing pa­tients as con­sumers. Our in­trepid IT re­porter Rachel Z. Arndt will be on site in San Diego to get a sense of what’s keep­ing CIOs up at night. Top­ping her list: What are CIOs do­ing to min­i­mize the risk of never-end­ing cy­ber­at­tacks?

OCT. 31: Wall Street watch­ers pre­dict a bag full of treats when An­them re­leases its third-quar­ter earn­ings. Rev­enue should hit $22.91 bil­lion, ac­cord­ing to Zacks In­vest­ment Re­search, up 3.7% from the same pe­riod last year. Oth­ers hop­ing not to spook the mar­kets with Q3 re­sults in­clude Bax­ter In­ter­na­tional, Ex­press Scripts, Glax­oSmithK­line and Molina Health­care. NOV. 1: The earn­ings marathon con­tin­ues with the likes of Ab­bVie, Allscripts, Cigna, Novo Nordisk and Teva Phar­ma­ceu­ti­cals post­ing re­sults.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.